Big Pharma Bets $100M on Take-Home 'Tripless' Psychedelics

BEDFORD, Mass. – November 09, 2026 – For decades, the psychiatric field has been locked in a frustrating binary. On one side, traditional antidepressants that require weeks or months to take effect, often with lackluster results and systemic side effects. On the other, a renaissance of psychedelic therapies that, while remarkably effective at rapidly rewiring the brain, demand intense, hours-long clinical supervision that fundamentally limits patient access.

Now, the industry is betting heavily on a third way: neuroplastogens. Delix Therapeutics, a clinical-stage neuroscience company, has just closed an oversubscribed $100 million Series C financing round to advance this exact premise. Co-led by Johnson & Johnson’s corporate venture arm (JJDC, Inc.) and SV Health Investors’ Dementia Discovery Fund (DDF), the capital injection signals a major strategic validation for drugs that aim to deliver the brain-healing benefits of psychedelics without the hallucinogenic trip.

The fresh funding will propel the company’s lead candidate, Zalsupindole, into a Phase IIb proof-of-concept trial for recurrent Major Depressive Disorder (MDD) in the first half of 2027. If successful, this compound could redefine the "how-to" of modern psychiatric care, shifting the paradigm from managing symptoms with daily pills to actively repairing neural circuitry with a scalable, take-home medicine.

The Promise of the 'Tripless' Trip

To understand the enthusiasm behind this $100 million raise, one must look at the mechanics of Zalsupindole. Inspired by 5-MeO-DMT—a potent psychedelic naturally found in certain plants and the venom of the Colorado River toad—Zalsupindole has been reverse-engineered to strip away the hallucinatory, dissociative, and sedative properties of its predecessor.

What remains is a true neuroplastogen: a molecule capable of promoting rapid structural and functional neural plasticity. In a recent Phase Ib trial involving 18 adults with recurrent MDD, the results were striking. Patients experienced an approximate 50 percent mean reduction in their Montgomery-Åsberg Depression Rating Scale (MADRS) scores—translating to roughly a 12-point drop—after just one week of treatment. Crucially, these improvements were maintained through Day 36, a full four weeks after the final dose.

Across more than 120 participants studied to date, the compound has demonstrated a favorable safety profile with absolutely no psychotomimetic effects. This is the critical differentiator. Classic psychedelics like psilocybin, or even approved dissociatives like Johnson & Johnson’s own Spravato (esketamine), require patients to be monitored in a certified clinic for hours due to the altered states of consciousness they induce. By uncoupling the neuroplastic healing from the psychedelic trip, Zalsupindole is designed to be taken at home, removing the massive logistical and financial bottlenecks that currently throttle the psychedelic medicine rollout.

Strategic Validation from a Neuroscience Giant

The participation of Johnson & Johnson Innovation is perhaps the most telling aspect of this Series C. As the manufacturer of Spravato, J&J possesses unparalleled insight into the commercial and operational realities of administering rapid-acting, clinic-bound psychiatric drugs. Their investment in a non-hallucinogenic alternative indicates a clear recognition that the future of mental healthcare relies on scalability.

"We are proud to welcome our new investors alongside the continued support of our existing shareholders as Delix enters its next stage of growth," said Mark Rus, Chief Executive Officer of Delix Therapeutics. "The strength and validation of this syndicate reflects the growing conviction and data for neuroplastogens as an important new therapeutic class. This capital enables us to take Zalsupindole through Phase II Proof of Concept, advance a broader pipeline of differentiated medicines, and build Delix for the long term."

A representative from JJDC has officially joined the board of directors, bringing decades of neuroscience-specific investment experience. This strategic alignment suggests that major pharmaceutical players are no longer just observing the psychedelic space from the sidelines; they are actively funding the next generation of optimized, patient-friendly analogues.

A Holy Grail for Alzheimer’s and Parkinson’s?

While depression is the immediate target, the implications of neuroplastogens extend far beyond mood disorders. The co-leadership of the Series C by SV Health Investors’ Dementia Discovery Fund highlights a fascinating pivot in the neuroscience of aging.

In neurodegenerative diseases like Alzheimer's and Parkinson's, cognitive decline is intimately tied to synaptic loss—the literal pruning and death of the connections between neurons. This synaptic degradation often correlates more strongly with cognitive impairment than the presence of amyloid plaques. The therapeutic hypothesis here is profound: if a drug can stimulate the rapid growth of dendritic spines and rebuild synaptic density in a depressed brain, could it do the same for a brain ravaged by dementia?

"We have been following the psychedelics field, and Delix is the first company we’ve seen to separate the neuroplastic benefits of psychedelics from their hallucinogenic effects," commented Dr. Christian Jung, Partner at SV Health Investors, DDF, who has also joined the board. "Alongside their encouraging clinical data, we are particularly excited by their ability to increase synaptic density across multiple preclinical models of Alzheimer’s and Parkinson’s disease, something of a holy grail for the field. I look forward to working with Mark, the Delix team and the other investors as they bring this pipeline forward."

With the expanded funding, the Bedford-based biotech plans to fulsomely progress its neurodegeneration programs into clinical stages. If preclinical efficacy signals translate to human trials, it would represent a monumental shift from merely slowing the progression of dementia to actively repairing the damaged neural architecture.

Navigating a Maturing Competitive Landscape

The firm is not alone in its quest to commercialize non-hallucinogenic neuroplastogens. The sector is rapidly maturing, with competitors like Gilgamesh Pharmaceuticals and Enveric Biosciences advancing their own novel chemical entities. Gilgamesh recently secured a partnership with AbbVie worth up to $1.2 billion, underscoring the massive market appetite for these compounds.

However, the successful closure of this oversubscribed round positions the company at the vanguard of the pack. The FDA has already cleared the Investigational New Drug (IND) application for a Phase II trial design that includes at-home self-administration, a regulatory green light that validates the safety profile established in early-stage human testing.

"We are thrilled with the addition of these outstanding new Board members," noted Nick Haft, Partner at OMX Ventures and company Co-Founder. "Their combined perspectives add important strategic depth as Delix enters its next stages of clinical and corporate development."

As we look toward the initiation of the Phase II trial in 2027, the stakes are incredibly high. Major Depressive Disorder affects over 280 million people globally, representing the primary cause of disability worldwide. The current standard of care leaves a vast unmet need, and the healthcare system simply lacks the infrastructure to provide guided psychedelic therapy to every patient who needs it. By engineering the trip out of the treatment, the industry may finally be on the verge of delivering the brain-healing power of psychedelics to the masses, straight to their medicine cabinets.